Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:52:23.144Z.
Consensus retrieved: 2026-10-06T13:58:29.730Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:52:23.144Z.
Quote observation: 2026-10-06T16:48:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c08b3608e0ca1050f1c615859c47b7d771d68d6464c45c5b3a212101f64634b2
Forward PE Ratio (N/A) = Dated Quote Price ($136.65) / Consensus Forward EPS ($10.19)
FORWARD PE RATIO
N/A
Mesa Laboratories, Inc.
Market Cap
$764.65M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Mesa Laboratories, Inc. (MLAB) | $764.65M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $767.66M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $754.64M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | N/A |
| Sana Biotechnology, Inc. (SANA)vs › | $777.83M | N/A |
| Apnimed, Inc. (APMD)vs › | $785.11M | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.07M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $735.87M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $735.73M | N/A |
Trailing P/E
162.7
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $10.19 implies +1113.1% EPS growth vs the reported trailing $0.84.
At the dated quote price of $136.65, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $10.19 | $10.02 – $10.36 | 1 | 13.4x |
| 2028-03-31 | $10.88 | $10.70 – $11.07 | 1 | 12.6x |
| 2029-03-31 | $0.00 | $0.00 – $0.00 | 0 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
